A comparison of oral and intravenous pimonidazole in canine tumors using intravenous CCI-103F as a control hypoxia marker
- 1 February 2006
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 64 (2) , 592-602
- https://doi.org/10.1016/j.ijrobp.2005.09.010
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Effect of Low Glutamine/Glucose on Hypoxia-Induced Elevation of Hypoxia-Inducible Factor-1α in Human Pancreatic Cancer MiaPaCa-2 and Human Prostatic Cancer DU-145 CellsClinical Cancer Research, 2005
- Quantifying Transient Hypoxia in Human Tumor Xenografts by Flow CytometryCancer Research, 2004
- Clinical studies of hypoxia modification in radiotherapySeminars in Radiation Oncology, 2004
- Modulating the Redox Property of a Flavin Analog Through Adjustment of Its Microenvironment in a Self-Assembled MonolayerAntioxidants and Redox Signaling, 2001
- Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroidsInternational Journal of Cancer, 1995
- ELISA quantification of CCI-103F binding in canine tumors prior to and during irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1994
- Effects of hypoxia and reoxygenation of the conversion of xanthine dehydrogenase to oxidase in Chinese hamster V79 cellsFree Radical Biology & Medicine, 1991
- Development of an in vivo19F magnetic resonance method for measuring oxygen deficency in tumorsMagnetic Resonance in Medicine, 1991
- A clinical phase I toxicity study of Ro 03–8799: plasma, urine, tumour and normal brain pharmacokineticsThe British Journal of Radiology, 1986
- Protonation of the Radical-anions of Nitro-imidazole Radiosensitizers and the Formation of Radical-adductsInternational Journal of Radiation Biology, 1975